Question to the Department for Business, Energy and Industrial Strategy:
To ask Her Majesty's Government what plans they have to undertake a strategic review of the role biologics manufacturing could play in pandemic responsiveness and resilience.
Currently the UK does not have the capability or scale to manufacture bulk levels of antibodies; the Vaccine Taskforce identified this as a potential weakness in the UK’s future pandemic response.
As a result, the Government issued a Prior Information Notice in October 2020 to engage with the market to explore how UK antibody manufacturing capability can be developed to secure permanent UK access and build resilience. The findings from the market engagement exercise, and the wider landscape of the pandemic, has resulted in the need for a broader strategic review of the role that biologics manufacturing could play in pandemic responsiveness and resilience.
The Government has invested over £300 million to secure and scale-up the UK’s vaccine manufacturing capabilities to be able to respond to the pandemic. This includes:
a) Facilities that have come online:
b) Facilities that will come online later this year, to help provide longer term UK capacity and will help in pandemic preparedness:
In addition to the above, we have also funded the expansion of the Valneva factory in Livingston, Scotland.